Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOBLE: Nivolumab + Relatlimab + GC vs Nivolumab + GC in Advanced Biliary Tract Cancer
NCT07369791Phase 2Withdrawn
- Sponsor
- National Health Research Institutes
- Start
- Dec 2026
- Primary completion
- Dec 2035
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab in biliary tract cancer (BTC), sponsored by National Health Research Institutes. Planned start Dec 2026; status: withdrawn.
02
Drugs
relatlimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07369791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07369791.